1472 results
What are the challenges for TAVI in bicuspid disease?
16 May 2024 – From EuroPCR 2024
Raj Makkar and Didier Tchétché address the complexities of bicuspid aortic valve disease, defining ideal candidates for TAVI or replacement and reviewing the NOTION-2 trial, which randomized younger, low-risk patients—including a significant number with bicuspid valves—to TAVI versus surgery. They highlight the importance of embolic protection...
Interventions for valvular disease: Highlights of EuroPCR 2024
16 May 2024 – From EuroPCR 2024
Christopher Cook hosts Nicolas Dumonteil and Bernard Prendergast as they share EuroPCR 2024 insights on valve disease interventions. Nicolas Dumonteil highlights record-breaking abstracts and cases, demonstrating expertise in TAVI, mitral, and tricuspid procedures. Bernard Prendergast emphasizes LIVE cases, especially in complex TAVI scenarios, reflecting everyday practice. Both stress...
What are the key considerations for first-time TAVI in a patient with long life expectancy?
15 May 2024 – From EuroPCR 2024
Interviewed by Dan Blackman, Philip Maccarthy discusses the rising trend of TAVI in younger patients and emphasizes optimizing first-TAVI procedure outcomes for long-term durability. He highlights considerations such as haemodynamics, low gradient, and minimizing paravalvular leak (PVL), as well as the importance of coronary access and...
NOTION-2: first TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid aortic valve stenosis
15 May 2024 – From EuroPCR 2024
Christopher Cook interviews Ole de Backer about this study he presented at EuroPCR 2024: It provides further data concerning the 1-year outcome of younger AS patients with tricuspid valve anatomy treated with TAVI compared to SAVR. TAVI and SAVR showed similar rates of the primary endpoint...
Asymptomatic severe aortic stenosis, how will new evidence change our practice?
15 May 2024 – From EuroPCR 2024
Victoria Delgado and Martin Leon discuss how to treat patients with asymptomatic severe aortic stenosis at an earlier stage and how current trials may change our practice in the future and broaden the indications.
This interview was filmed at EuroPCR 2024: see more videos here.
First report of an IDE pivotal study of a dedicated splitting device during TAVR
15 May 2024 – From EuroPCR 2024
Watch this interview in which Christopher Cook hosts Martin Leon to discuss pivotal study data on the ShortCut dedicated leaflet splitting device. They revisit the unmet clinical need for leaflet splitting during TAVR: transcatheter valve failures, noting that transcatheter valve failures could surpass surgical bioprosthetic valve failures...
The LANDMARK trial: early outcomes of a randomised non-inferiority trial comparing TAVI devices
15 May 2024 – From EuroPCR 2024
In this video, Christopher Cook interviews Patrick Serruys about the late-breaking clinical trial data from the LANDMARK RCT. Patrick Serruys begins by explaining the LANDMARK trial, which compares TAVI devices, and emphasizes the complexity of applying VARC-3 criteria. He highlights that the 30-day outcomes confirm the...
ShortCut leads the way for leaflet modification
14 May 2024 – From EuroPCR 2024
Check out this interview with Philippe Genereux, Danny Dvir and Susheel Kodali, where they discuss the ShortCut trial. Learn about the ShortCut device, the first tool for splitting leaflets in valve-in-valve procedures. Hear key insights, including the dual splitting technique, comparisons between BASILICA and ShortCut, and...
Innovations in transcatheter valve interventions: moving the flow in the right direction
13 May 2024 – From EuroPCR 2024
Comparison of two self-expanding transcatheter heart valves for degenerated surgical bioprostheses: the AVENGER multicentre registry
15 Apr 2024
This trial sought to compare the procedural and clinical outcomes of ACURATE neo/neo2 and EVOLUT R/PRO/Pro+ valves for ViV procedures.
Reviewer
Reviewer
Self-expanding versus balloon-expandable transcatheter aortic valve replacement in patients with small aortic annuli: Primary outcomes from the randomized SMART Trial
07 Apr 2024
Alessandro Sticchi interviews Howard C. Herrmann about the primary outcomes from the randomized SMART Trial which he presented at ACC.24 in Atlanta.
Patients with severe aortic stenosis and small aortic annuli, typically female and often underrepresented in clinical trials, are at risk for impaired valvular hemodynamics and associated...
Author
Author
PCRonline @ ACC.24 Scientific Sessions
22 Mar 2024
Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2024 Scientific Sessions #ACC24
Non–vitamin K antagonist versus vitamin K antagonist oral anticoagulant agents after transcatheter aortic valve replacement
19 Mar 2024
This study demonstrates that, at 5 years post TAVI in patients with an indication for OAC, the net clinical benefit did not differ between the VKA and DOAC groups.
Reviewer
Reviewer
Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial
13 Mar 2024
The NOTION trial provides the first ten-year data comparing clinical outcomes and valve durability between TAVI and SAVR in the lower risk population.
Reviewer
TAVI versus SAVR in patients at low to intermediate risk: One year outcomes of the randomized DEDICATE-DZHK6 Trial
08 Apr 2024
Luigi Biasco interviews Moritz Seiffert about the one-year outcomes of the randomized DEDICATE-DZHK6 trial which he presented at ACC.24 in Atlanta.
TAVR was found non-inferior to SAVR in low-risk patients, showing decreased rates of death or stroke at one year. The trial supports TAVR's safety and efficacy, highlighting...
Author
Author
Protein and exercise to reverse frailty in older men and women undergoing transcatheter aortic valve replacement: The PERFORM-TAVR Trial
08 Apr 2024
Panos Xaplanteris provides his take on the results of PERFORM-TAVR presented by Jonathan Afilalo at ACC.24 in Atlanta.
Author
Contemporary techniques for TAV-in-SAV interventions
18 Feb 2024 – From PCR Tokyo Valves 2024
Thanks to this session, take a look at the current outcomes of TAV-in-SAV, analyse the different types of valves and their fracturability, find out more, through case studies, about two different TAV-in-SAV techniques, with or without a stent, and learn how to avoid patient prosthesis mismatch...
Shaping the future of structural heart disease intervention
18 Feb 2024 – From PCR Tokyo Valves 2024
Consult this session if you want to discuss the remaining challenges of transcatheter valvular interventions, and to review latest innovations for structural heart disease.
New devices for aortic intervention
18 Feb 2024 – From PCR Tokyo Valves 2024
In this session, discover a variety of abstract submissions concerning new devices for aortic intervention. Compare the clinical outcomes of the latest intra-annular devices, examine the differences in debris between SEV and PEV, and learn about PVL improvement after TAVI with a self-expanding valve.
Rapid-fire - Bailout in TAVI
18 Feb 2024 – From PCR Tokyo Valves 2024
As TAVI is never risk-free, learn about bailout techniques to counter various complications through this series of rapid-fire case submissions. This session explores cases such as a transcatheter aortic valve distortion following cardiopulmonary resuscitation, acute transcatheter aortic valve migration into the left ventricle, and valve embolization.
